Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment
Phase 2
Completed
- Conditions
- Colorectal CancerNon-Small Cell Lung CancerProstate CancerSolid TumorsAdvanced Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2008-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT00425204
Safety and Efficacy Study of ABX-EGF in Patients With Renal Cancer, Part 2
Phase 2
Completed
- Conditions
- Advanced Renal Cell Carcinoma
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 115
- Registration Number
- NCT00425035
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Phase 2
Completed
- Conditions
- CancerColon CancerColorectal CancerMetastatic CancerRectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 266
- Registration Number
- NCT00418938
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving Revlimid
Phase 2
Completed
- Conditions
- Myelodysplastic SyndromesThrombocytopenia
- Interventions
- Drug: PlaceboBiological: AMG 531
- First Posted Date
- 2007-01-05
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 39
- Registration Number
- NCT00418665
Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
Phase 3
Completed
- Conditions
- ThrombocytopeniaIdiopathic Thrombocytopenic PurpuraThrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)Thrombocytopenic Purpura
- Interventions
- Biological: RomiplostimDrug: Medical Standard of Care for ITP
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 234
- Registration Number
- NCT00415532
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Chemotherapy-Induced ThrombocytopeniaSolid TumorsThrombocytopeniaLung CancerOncologyNon-Small Cell Lung CancerCancerLung Neoplasms
- Interventions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2013-10-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 63
- Registration Number
- NCT00413283
- Locations
- 🇵🇹
Research Site, Vila Nova de Gaia, Portugal
Etanercept SFP in RA Patients
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 224
- Registration Number
- NCT00413452
Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
Phase 2
Completed
- Conditions
- Colon CancerColorectal CancerRectal CancerCancerMetastatic CancerMetastatic Colorectal CancerOncology
- Interventions
- Biological: PanitumumabDrug: FOLFIRI
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 116
- Registration Number
- NCT00411450
Darbepoetin Alfa With or Without Intravenous (IV) Iron
Phase 2
Completed
- Conditions
- Non-Myeloid MalignanciesAnemia
- Interventions
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2014-01-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 243
- Registration Number
- NCT00401544
Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
Phase 2
Completed
- Conditions
- Giant Cell Tumor of BoneGCT
- Interventions
- Biological: DenosumabDietary Supplement: Calcium/Vitamin D
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 37
- Registration Number
- NCT00396279
© Copyright 2025. All Rights Reserved by MedPath